SCHEMBL643253

SCHEMBL643253

CN(C)C(CCc1ccccc1)C1CCC(NC(=O)C2Cc3ccccc3N2S(=O)(=O)c2ccc(Cl)c(Cl)c2)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 3/20 0.43
LMNA P02545 1/20 0.41
MMP9 P14780 1/20 0.39
CCR4 P51679 3/20 0.38
PTGER3 P43115 1/20 0.38
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37
PSENEN Q9NZ42 1/20 0.37
RAB9A P51151 1/20 0.37
CYP2C9 P11712 1/20 0.36
CCR10 P46092 1/20 0.36
APP P05067 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ACE P12821 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL643833 0.90 BDKRB1 (0.41) BDKRB1MMP9PTGER3PSEN1PSEN2
SCHEMBL645419 0.88 BDKRB1 (0.42) BDKRB1MMP9PTGER3PSEN1PSEN2
SCHEMBL644671 0.86 LMNA (0.43) BDKRB1LMNAMMP9CCR4PTGER3
SCHEMBL644236 0.82 LMNA (0.41) BDKRB1LMNACCR4PTGER3RAB9A
SCHEMBL645393 0.81 LMNA (0.42) BDKRB1LMNAPTGER3RAB9AHPGD
SCHEMBL927220 0.79 BDKRB1 (0.51) BDKRB1MMP9PTGER3PSEN1PSEN2
SCHEMBL642869 0.76 CACNA1H (0.42) BDKRB1PTGER3PSEN1PSEN2APH1B
SCHEMBL643004 0.73 ALDH1A1 (0.48) BDKRB1LMNAPTGER3
SCHEMBL644139 0.72 ALDH1A1 (0.47) BDKRB1LMNAPTGER3SMN1; SMN2
SCHEMBL2490288 0.71 CACNA1H (0.43) BDKRB1LMNAPTGER3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2150530-B1 SUBSTITUTED SULFONAMIDE DERIVATIVES GRUENENTHAL GMBH (DE) 2011-10-26 EP claimed
US-20080312231-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2008-12-18 US claimed
US-8119633-B2 N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases GRUENENTHAL GMBH (DE) 2012-02-21 US disclosed
EP-2150530-B1 SUBSTITUTED SULFONAMIDE DERIVATIVES GRUENENTHAL GMBH (DE) 2011-10-26 EP disclosed
EP-2150530-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-02-10 EP disclosed
US-20080312231-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed
WO-2008131947-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312231-A1 Substituted Sulfonamide Compounds SULT2A1, SULT1A1, SCN1A BDKRB1 1566/4885LMNA 2721/4885MMP9 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.